Johnson & Johnson $JNJ Holdings Lifted by Burford Brothers Inc.

Burford Brothers Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 73.6% in the 1st quarter, Holdings Channel reports. The fund owned 15,556 shares of the company’s stock after purchasing an additional 6,595 shares during the period. Johnson & Johnson makes up about 1.6% of Burford Brothers Inc.’s portfolio, making the stock its 12th biggest position. Burford Brothers Inc.’s holdings in Johnson & Johnson were worth $3,803,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of JNJ. Sierra Capital LLC lifted its position in shares of Johnson & Johnson by 0.5% in the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after purchasing an additional 41 shares in the last quarter. Beaird Harris Wealth Management LLC grew its position in Johnson & Johnson by 1.8% during the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock valued at $501,000 after purchasing an additional 42 shares in the last quarter. Broadleaf Partners LLC increased its stake in Johnson & Johnson by 0.6% in the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock valued at $1,521,000 after buying an additional 43 shares during the period. Jessup Wealth Management Inc lifted its position in Johnson & Johnson by 0.6% in the 4th quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock worth $1,567,000 after buying an additional 44 shares in the last quarter. Finally, Plancorp LLC lifted its position in Johnson & Johnson by 0.3% in the 4th quarter. Plancorp LLC now owns 15,889 shares of the company’s stock worth $3,288,000 after buying an additional 45 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.4%

Shares of NYSE:JNJ opened at $259.31 on Tuesday. The company has a market cap of $624.22 billion, a P/E ratio of 29.98, a P/E/G ratio of 2.58 and a beta of 0.24. The stock’s 50-day moving average is $233.72 and its 200-day moving average is $231.37. Johnson & Johnson has a 52-week low of $154.21 and a 52-week high of $263.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same quarter in the previous year, the firm earned $2.77 EPS. The firm’s revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on JNJ. Morgan Stanley set a $283.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 15th. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research report on Wednesday, April 15th. TD Cowen assumed coverage on Johnson & Johnson in a research note on Wednesday, April 8th. They issued a “buy” rating and a $250.00 target price on the stock. HSBC set a $290.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday. Finally, Barclays lifted their price target on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $257.13.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.